Fyarro
Payments companies reported to CMS as associated with Fyarro. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fyarro, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fyarro
These are the largest totals companies reported as associated with Fyarro. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ralph Boccia | Bethesda, MD | Hematology & Oncology | $83,614.89 |
| Caley Castelein | Miami Beach, FL | General Practice | $78,000.00 |
| George Demetri | Boston, MA | Medical Oncology | $47,474.66 |
| Susan Jerian | Westlake Village, CA | Internal Medicine | $44,450.00 |
| Leslie Worona | New York, NY | Family | $42,432.26 |
| Kamalesh Sankhala | Beverly Hills, CA | Medical Oncology | $39,653.65 |
| Veronica Vestal | Toa Baja, PR | Hematology & Oncology | $33,112.43 |
| Arun Singh | Santa Monica, CA | Hematology & Oncology | $24,816.93 |
| Thomas Herzog | Cincinnati, OH | Gynecologic Oncology | $23,690.55 |
| Scott Penney | San Antonio, TX | Pediatric Hematology-Oncology | $21,927.43 |
Prescribed Fyarro?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.